We are a diversified healthcare group that is developing, investing in and delivering a range of exciting new technologies and leading edge medical devices that have the potential to make a real difference to the outcomes and quality of life of patients around the globe.
Avoid the “variability” of the elastomeric technology. ambIT® infusion pumps require less intervention, minimise risk of dosing errors and ensure that pain is controlled.Read More
Admedus has a portfolio of technology at various stages of development that target areas of significant clinical need. R and D projects, medical technologies in clinical trial, products pending market approval and a strong distribution business supplying medical devices to the healthcare market.Read More
Our immunotherapies R and D partnership with Professor Ian Frazer is researching and commercialising new vaccines to prevent diseaseRead More
Lead by Professor Ian Frazer our therapeutic vaccines now in Phase 1 trial will treat a range of infectious diseases and cancersRead More
First of our Regenerative Tissue products,CardioCel,a cardiovascular patch, available in Europe and seeking global approval.Read More
Our sales and distribution business is taking innovative infusion products to the Australasian healthcare market and making a difference to patientsRead More
Admedus receives Frost & Sullivan 2014 Australian Healthcare Award for Life Sciences New Product Innovation of the Year
Admedus (ASX: AHZ) today announced it has received FDA clearance to market CardioCel® in the US.
Admedus announced the completed acquisition of an established manufacturing site to scale up production of CardioCel
Admedus - An exciting new global branding program as part of the expansion of our business into new markets.
Channel 7 Brisbane - Babies with heart defects treated with CardioCel